Clinical trial
Investigation of Biomarker Response to SGLT2 Inhibition Across Various Phenotypes of Heart Failure
NCT06140251 is registered in ClinicalTrials.gov with Queen's University, Belfast as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Investigation of Biomarker Response to SGLT2 Inhibition Across Various Phenotypes of Heart Failure
- Lead sponsor
- Queen's University, Belfast
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- August 21, 2023
- Completion date
- May 1, 2025
- Enrollment
- 68 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.